Balchem Cashes a Two-Year Rain Check on Choline — Right at the Doorstep of a Record High
Record revenue, a 29-quarter EBITDA streak, and a long-teased Alzheimer's-adjacent pilot finally in print — but the market's oil-inflation trade is this company's cost line, not its tailwind
BCPC · Earnings Call · 2026-10-23
A good quarter into a stock that already knows it
Balchem's third quarter was, by the company's own scorecard, the best it has ever posted: record consolidated sales of $291 million, up 8.6%; record GAAP earnings from operations of $62 million, up 14.4%; record adjusted EBITDA of $80 million, up 12.4%. Ted Harris framed it as continuity rather than arrival: “The third quarter marked our 29th consecutive quarter of year over year growth in adjusted EBITDA.” — Theodore L. Harris, Chairman and President · 2026-10-23 The tape has noticed. At roughly $177 the shares sit about 3.5% below their November 2024 peak of $183.41, up 7.7% over the last 90 trading days on a single, unbroken up-leg. This is not a turnaround story told into a depressed price — it is a compounder reporting into a price that already discounts a good deal of compounding. So the interesting question is not what happened, but which parts of the quarter are genuinely new.Choline grows up — and this time it is in print
The genuinely new item is science. Two publications landed: the MD Anderson / University of Texas pilot study on choline supplementation in cognitively healthy APOE4 carriers, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, and the DANCODE trial on Balchem's K2VITAL DELTA, published in Circulation, examining coronary artery calcification across some 400 subjects. That is what pushed adult cognition to the top of the company's keyword stack this quarter, with cardiovascular benefit, MD Anderson, pilot study and healthy aging arriving alongside it. This is a promise kept, not a new promise made. On the July call Harris told analysts: “we do expect that study should be published in the next couple of months... I am really hopeful that with the next quarterly update, I will be able to talk about the results of that study.” — Theodore L. Harris, Chairman, President, and CEO · 2026-07-31 And back in April he had already framed the stakes: “this could be an absolute breakthrough from a Vidacholine perspective and really open up that... huge adult cognition market.” — Ted Harris, Chairman, President, and CEO · 2026-04-30The honesty matters: Harris called it “a fairly small group of participants” — Theodore L. Harris, Chairman and President · 2026-10-23 that “will lead to a much bigger study.” — Theodore L. Harris, Chairman and President · 2026-10-23 The commercial move is marketing, not a revenue line — the company will “create awareness around studies like this through our marketing efforts.” — Theodore L. Harris, Chairman and President · 2026-10-23 That is a second-derivative catalyst with a multi-year fuse. And it is genuinely company-unique. Scanning the dozens of reporters in the recent window, nobody else is monetising cognition-adjacent nutrients; the nearest shared language is the generic clinical body of evidence motif. Balchem is not riding a wave here. It is building a moat, brick by peer-reviewed brick, around its branded ingredients.choline has predominantly been recognized as an important nutrient for child nutrition, infant nutrition... And this study is clearly focusing on adult cognition.
The mix tailwind is real — and it is not new
What actually drove the margin was the same portfolio-mix story management has been telling for at least three quarters. Asked to elaborate, Martin Bengtsson was candid: “there is some favorable tailwinds just from a portfolio perspective” — Carl Martin Bengtsson, Chief Financial Officer · 2026-10-23 — nutrients growing faster than food ingredients inside Human Nutrition & Health, ruminant dairy growing faster than monogastric inside Animal Nutrition, and high-margin Specialty Products on top. The identical point appeared on the April call, when he noted “our higher-margin businesses are the ones growing the fastest” — Martin Bengtsson, Chief Financial Officer · 2026-04-30. This is a durable structural tailwind, not a fresh discovery. Gross margin reached 36.4%, up 70 basis points year over year — a record, on a series that has climbed steadily since 2016. Operating margin now sits at 20.9%, up from the mid-teens two years ago. Inflation was passed through dollar-for-dollar, leaving the company roughly breakeven year to date, and the residual dilution to margin rate was more than offset by mix. The increment worth noting: Animal Nutrition earnings from operations rose 82.8% to $6.8 million — an enormous percentage on a small base. The driver is antidumping relief in Europe (regained volumes, firmer pricing), plus a pricing action in U.S. monogastric, plus a new encapsulated lysine line and a next-generation encapsulated methionine rolled out on October 1, just after the quarter closed.The global oil trade is a headwind here
Here is the sharpest contrast in the report. The global keyword set is dominated by High oil, High fuel costs and elevated bunker prices — an inflation trade the whole market is voting on. For Balchem, that tape is a cost line wearing a tailwind's clothes. Oil price surged to the number two slot in the company's own keyword stack, and Bengtsson dismantled the bull case in one breath: the fracking-linked choline chloride business was a $105 million business twelve years ago, $5 million last year, and is now running at maybe $8 million because the industry reformulated and reuses fluids.That is an unusually direct disavowal of an obvious analyst narrative, and it is consistent with the company's own logic: oil feeds transport, utilities and petrochemical-derived Raw material costs. Anyone modelling an energy-driven upside surprise into this name is modelling the wrong sign.So net, I would probably say that high oil prices is not necessarily a good thing for us. It would be a net negative for us... We would actually be quite happy if those oil prices started easing off.